HSBC Holdings’s TG Therapeutics TGTX Stock Holding History

HSBC Holdings’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,000	Closed	-$89.8K	–	3156
2024 Q2	$89.8K	Buy	+5,000	New	+$79.8K	﹤0.01%	2750
2024 Q1	–	Sell	-1,000	Closed	-$17.1K	–	3233
2023 Q4	$17.1K	Buy	+1,000	New	+$11.6K	﹤0.01%	2687
2023 Q3	–	Sell	-3,500	Closed	-$84.4K	–	2848
2023 Q2	$84.4K	Buy	+3,500	New	+$90.4K	﹤0.01%	2458
2021 Q2	–	Sell	-4,000	Closed	-$193K	–	3081
2021 Q1	$193K	Buy	+4,000	New	+$192K	﹤0.01%	2555
2020 Q4	–	Sell	-3,000	Closed	-$80K	–	3144
2020 Q3	$80K	Sell	3,000 -7,000	-70%	-$161K	﹤0.01%	2649
2020 Q2	$195K	Buy	+10,000	New	+$161K	﹤0.01%	2379
2019 Q3	–	Sell	-6,000	Closed	-$52K	–	3154
2019 Q2	$52K	Buy	6,000 +4,000	+200%	+$30.2K	﹤0.01%	2655
2019 Q1	$16K	Buy	+2,000	New	+$10.8K	﹤0.01%	2682

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HSBC Holdings's TGTX Position: Q1 2026 in Review

HSBC Holdings reduced its TG Therapeutics (TGTX) stake by 27% in Q1 2026, selling an estimated $1.18M and leaving 106,344 shares worth $3.56M. The position accounts for ﹤0.01% of the portfolio, ranked #1286.

HSBC Holdings first reported a position in TGTX in Q2 2018 and has held it in 17 quarters since. The position peaked at $4.37M in Q4 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

HSBC Holdings held 106,344 shares of TG Therapeutics worth $3.56M as of Q1 2026.
HSBC Holdings sold 39,743 TG Therapeutics shares in Q1 2026, an estimated $1.18M.
TG Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #1286 holding.
HSBC Holdings first reported a position in TG Therapeutics in Q2 2018 and has held it in 17 quarters since.
HSBC Holdings's TG Therapeutics position peaked at $4.37M in Q4 2025.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.